November 11, 2019
Vaccibody with first neoantigen cancer vaccine to show induction of strong cancer-specific immune responses
Vaccibody AS, a clinical-stage biopharmaceutical company focused on cancer vaccines, announced in a press release on November 5, 2019 the positive initial data from the ongoing VB N-01 (DIRECT-01) phase I/IIa clinical trial of the VB10.NEO neoantigen cancer vaccine.